ID

40466

Description

A Non-Interventional Study With Aromasin® As Adjuvant Treatment Of Invasive Early Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01121549

Link

https://clinicaltrials.gov/show/NCT01121549

Keywords

  1. 4/23/20 4/23/20 -
Copyright Holder

See clinicaltrials.gov

Uploaded on

April 23, 2020

DOI

To request one please log in.

License

Creative Commons BY 4.0

Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Invasive Early Breast Cancer NCT01121549

Eligibility Invasive Early Breast Cancer NCT01121549

Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
postmenopausal females, defined as one from the next :
Description

Postmenopausal state

Data type

boolean

Alias
UMLS CUI [1]
C0232970
1. natural menopause >/=1 year,
Description

Natural menopause Duration

Data type

boolean

Alias
UMLS CUI [1,1]
C0856856
UMLS CUI [1,2]
C0449238
2. surgical ovariectomy,
Description

Ovariectomy

Data type

boolean

Alias
UMLS CUI [1]
C0029936
3. chemotherapy-induced amenorrhoea >/=2 years.
Description

Amenorrhea Chemotherapy-induced | Amenorrhea Duration

Data type

boolean

Alias
UMLS CUI [1,1]
C0002453
UMLS CUI [1,2]
C0392920
UMLS CUI [1,3]
C0205263
UMLS CUI [2,1]
C0002453
UMLS CUI [2,2]
C0449238
patients who have had surgical treatment for histological confirmed breast cancer that was non-metastatic at the time of the initial diagnosis.
Description

Operative Surgical Procedure Breast Carcinoma nonmetastatic

Data type

boolean

Alias
UMLS CUI [1,1]
C0543467
UMLS CUI [1,2]
C0678222
UMLS CUI [1,3]
C1518409
patients who are disease-free after 2 or 3 years of adjuvant tamoxifen treatment.
Description

Patients Disease Free of | Status post Tamoxifen Adjuvant therapy

Data type

boolean

Alias
UMLS CUI [1,1]
C0030705
UMLS CUI [1,2]
C0012634
UMLS CUI [1,3]
C0332296
UMLS CUI [2,1]
C0231290
UMLS CUI [2,2]
C0039286
UMLS CUI [2,3]
C0677850
patients whose tumour was estrogen receptor positive (er+).
Description

Estrogen receptor positive tumor

Data type

boolean

Alias
UMLS CUI [1]
C1562312
evidence of a personally signed and dated informed consent document indicating that the subject (or a legally acceptable representative) has been informed of all pertinent aspects of the study.
Description

Informed Consent

Data type

boolean

Alias
UMLS CUI [1]
C0021430
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
patients for whom aromasin® treatment is contraindicated (see smpc).
Description

Medical contraindication Aromasin

Data type

boolean

Alias
UMLS CUI [1,1]
C1301624
UMLS CUI [1,2]
C0876723
presence of metastasis or a contra lateral tumour.
Description

Neoplasm Metastasis | Neoplasm Contralateral

Data type

boolean

Alias
UMLS CUI [1]
C0027627
UMLS CUI [2,1]
C0027651
UMLS CUI [2,2]
C0441988
other adjuvant endocrine therapy.
Description

Hormone Therapy Adjuvant

Data type

boolean

Alias
UMLS CUI [1,1]
C0279025
UMLS CUI [1,2]
C1522673
another concomitant antineoplastic treatment
Description

Cancer treatment Other

Data type

boolean

Alias
UMLS CUI [1,1]
C0920425
UMLS CUI [1,2]
C0205394
participation in a clinical trial with an investigational drug during the 30 days prior to enrolment in the study.
Description

Study Subject Participation Status | Investigational New Drugs

Data type

boolean

Alias
UMLS CUI [1]
C2348568
UMLS CUI [2]
C0013230
the patients are not supposed to participate to any other trial during all the study period.
Description

Study Subject Participation Status | Clinical Trial

Data type

boolean

Alias
UMLS CUI [1]
C2348568
UMLS CUI [2]
C0008976

Similar models

Eligibility Invasive Early Breast Cancer NCT01121549

Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
Postmenopausal state
Item
postmenopausal females, defined as one from the next :
boolean
C0232970 (UMLS CUI [1])
Natural menopause Duration
Item
1. natural menopause >/=1 year,
boolean
C0856856 (UMLS CUI [1,1])
C0449238 (UMLS CUI [1,2])
Ovariectomy
Item
2. surgical ovariectomy,
boolean
C0029936 (UMLS CUI [1])
Amenorrhea Chemotherapy-induced | Amenorrhea Duration
Item
3. chemotherapy-induced amenorrhoea >/=2 years.
boolean
C0002453 (UMLS CUI [1,1])
C0392920 (UMLS CUI [1,2])
C0205263 (UMLS CUI [1,3])
C0002453 (UMLS CUI [2,1])
C0449238 (UMLS CUI [2,2])
Operative Surgical Procedure Breast Carcinoma nonmetastatic
Item
patients who have had surgical treatment for histological confirmed breast cancer that was non-metastatic at the time of the initial diagnosis.
boolean
C0543467 (UMLS CUI [1,1])
C0678222 (UMLS CUI [1,2])
C1518409 (UMLS CUI [1,3])
Patients Disease Free of | Status post Tamoxifen Adjuvant therapy
Item
patients who are disease-free after 2 or 3 years of adjuvant tamoxifen treatment.
boolean
C0030705 (UMLS CUI [1,1])
C0012634 (UMLS CUI [1,2])
C0332296 (UMLS CUI [1,3])
C0231290 (UMLS CUI [2,1])
C0039286 (UMLS CUI [2,2])
C0677850 (UMLS CUI [2,3])
Estrogen receptor positive tumor
Item
patients whose tumour was estrogen receptor positive (er+).
boolean
C1562312 (UMLS CUI [1])
Informed Consent
Item
evidence of a personally signed and dated informed consent document indicating that the subject (or a legally acceptable representative) has been informed of all pertinent aspects of the study.
boolean
C0021430 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Medical contraindication Aromasin
Item
patients for whom aromasin® treatment is contraindicated (see smpc).
boolean
C1301624 (UMLS CUI [1,1])
C0876723 (UMLS CUI [1,2])
Neoplasm Metastasis | Neoplasm Contralateral
Item
presence of metastasis or a contra lateral tumour.
boolean
C0027627 (UMLS CUI [1])
C0027651 (UMLS CUI [2,1])
C0441988 (UMLS CUI [2,2])
Hormone Therapy Adjuvant
Item
other adjuvant endocrine therapy.
boolean
C0279025 (UMLS CUI [1,1])
C1522673 (UMLS CUI [1,2])
Cancer treatment Other
Item
another concomitant antineoplastic treatment
boolean
C0920425 (UMLS CUI [1,1])
C0205394 (UMLS CUI [1,2])
Study Subject Participation Status | Investigational New Drugs
Item
participation in a clinical trial with an investigational drug during the 30 days prior to enrolment in the study.
boolean
C2348568 (UMLS CUI [1])
C0013230 (UMLS CUI [2])
Study Subject Participation Status | Clinical Trial
Item
the patients are not supposed to participate to any other trial during all the study period.
boolean
C2348568 (UMLS CUI [1])
C0008976 (UMLS CUI [2])

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial